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The membrane-proximal external region (MPER) of HIV-1 gp41 is an attractive target for vaccine
development. Thus, better understanding of its immunogenic properties in various structural contexts is
important. We previously described the crystal structure of a trimeric protein complex named gp41-
HR1-54Q, which consists of the heptad repeat regions 1 and 2 and the MPER. The protein was efﬁciently
recognized by broadly neutralizing antibodies. Here, we describe its immunogenic properties in rabbits.
The protein was highly immunogenic, especially the C-terminal end of the MPER containing 4E10 and
10E8 epitopes (671NWFDITNWLWYIK683). Although antibodies exhibited strong competition activity
against 4E10 and 10E8, neutralizing activity was not detected. Detailed mapping analyses indicated that
amino acid residues critical for recognition resided on faces of the alpha helix that are either opposite of
or perpendicular to the epitopes recognized by 4E10 and 10E8. These results provide critical information
for designing the next generation of MPER-based immunogens.
& 2015 Elsevier Inc. All rights reserved.Introduction
The envelope glycoprotein of human immunodeﬁciency virus
type 1 (HIV-1) serves a critical role of mediating virus entry into
host cells. This protein is also immunologically important because
it is the sole target against which neutralizing antibodies are eli-
cited in infected individuals. The two subunits of the envelope
glycoprotein, gp120 and gp41, pose different sets of challenges for
HIV-1 vaccine design. Besides being heavily glycosylated and
highly variable, the gp120 subunit contains many immunodomi-
nant epitopes that act as decoys, which provide limited, if any,
protection (Pantophlet and Burton, 2006; Sodroski et al., 1998;
Wei et al., 2003). While several anti-gp120 broadly neutralizing
antibodies (bnAbs) have been isolated from infected individuals
(Blattner et al., 2014; Buchacher et al., 1994; Burton et al., 1991;
Diskin et al., 2011; Falkowska et al., 2014; Klein et al., 2012; Scharf
et al., 2014; Scheid et al., 2011; Walker et al., 2011, 2009; Wu et al.,
2010), most of the epitopes targeted by these antibodies are non-
linear and highly conformational. Hence, designing gp120 antigens
that can present the neutralizing epitopes in the correct con-
formation, while limiting response to other non-protective
immunodominant epitopes, has been a difﬁcult task..In comparison, gp41 is smaller, less variable and less glycosy-
lated. It contains a highly conserved domain (22 amino acid
residues) called the membrane-proximal external region (MPER)
that lies between heptad repeat region 2 (HR2) and the trans-
membrane (TM) domain. This MPER contains linear epitopes tar-
geted by a number of bnAbs, including 2F5, Z13e1, 4E10 and 10E8
(Huang et al., 2012; Kwong et al., 2013; and reviewed in Montero
et al., 2008; Purtscher et al., 1994; Stiegler et al., 2001; van Gils and
Sanders, 2013; Zwick et al., 2001). Unfortunately, the structure of
gp41 is thought to be highly dynamic, undergoing signiﬁcant
conformational changes upon receptor binding and during the
fusion process (Mao et al., 2013; Melikyan, 2008). In the native,
pre-fusion state, gp41 presumably exists in a metastable con-
formation that stores the free energy needed for membrane fusion.
Following gp120 binding to CD4 and to a co-receptor, gp41
transforms into a fusion-active intermediate in which the N-
terminal fusion peptide (FP) inserts into the host-cell membrane.
Subsequently, the two heptad repeat regions, HR1 and HR2, are
brought together to form a highly stable six-helix bundle, which
concomitantly leads to the formation of a hairpin structure that
completes the fusion of the viral and cellular membranes
(Melikyan, 2008). This metastable and transient nature of the gp41
structure has made it difﬁcult to design vaccine antigens that can
present epitopes in their native form so as to generate
potent bnAbs.
Signiﬁcant efforts have been made for developing MPER-based
vaccines (Montero et al., 2008). Some of the vaccine candidates
H.H. Habte et al. / Virology 486 (2015) 187–197188evaluated so far include immunogens based on short MPER pep-
tides, either alone or coupled to carrier proteins (Decroix et al.,
2001; Joyce, 2002; Liao et al., 2000; Matoba et al., 2006;
McGaughey et al., 2003; Ni et al., 2004); the use of artiﬁcial scaf-
folds containing stabilized MPER epitopes (Correia et al., 2010;
Guenaga et al., 2011; Ofek et al., 2010); hybrid/fusion proteins
(Coëfﬁer et al., 2000; Hinz et al., 2009; Krebs et al., 2014; Law et al.,
2007; Liang et al., 1999; Mantis et al., 2001; Strasz et al., 2014);
chimeric viruses or virus-like particles displaying MPER epitopes
(Arnold et al., 2009; Benen et al., 2014; Bomsel et al., 2011; Eckhart
et al., 1996; Jain et al., 2010; Kamdem Toukam et al., 2012; Kim
et al., 2007; Luo et al., 2006; Marusic et al., 2001; Muster et al.,
1995; Ye et al., 2011; Yi et al., 2013; Zhang et al., 2004); and pre-
sentation of MPER peptides on liposomes (Dennison et al., 2011;
Hanson et al., 2015; Hulsik et al., 2013; Lai et al., 2014; Matyas
et al., 2009; Mohan et al., 2014; Serrano et al., 2014; Venditto et al.,
2013, 2014). Despite these efforts, none of them succeeded in
inducing bnAbs against the MPER, albeit a few recent studies
reported induction of modest levels of cross-clade neutralizing
activity (Hulsik et al., 2013; Krebs et al., 2014; Lai et al., 2014; Ye
et al., 2011; Yi et al., 2013). These results highlight the difﬁculty in
eliciting anti-MPER bnAbs through vaccination.
There likely are multiple reasons for these unsuccessful attempts.
Short peptide-based immunogens might be lacking helper T cell
epitopes that are needed to induce robust CD4þ T cell immunity. In
addition, peptides, in the absence of neighboring domains, might not
fold into the conformation that may exist in the native trimeric
envelope spikes on virus particles. However, merely mimicking bnAb-
bound conformations might not be sufﬁcient to elicit such antibodies
since MPER epitopes constrained in artiﬁcial scaffolds also failed to
elicit bnAbs (Correia et al., 2010; Guenaga et al., 2011; McGaughey
et al., 2003; Ofek et al., 2010). Chimeric viruses with MPER grafts have
shown to induce poor anti-MPER antibody titers (Eckhart et al., 1996;
Kusov et al., 2007; Luo et al., 2006; Zhang et al., 2004). This could be
due to the presence of other epitopes that might be more immuno-
genic than the MPER and distract immune responses away from it.
Thus, the relative immunogenicity of the target epitope is important
when in the context of a large protein. Finally, choosing appropriate
adjuvants could also be an important factor, not only for enhancing
immune responses per se, but also for making sure that the adjuvantFig. 1. Generation of gp41-HR1-54Q. (A) A domain structure of gp41 ectodomain is show
HR1 (heptad repeat region 1), immunodominant C-C loop, HR2 (heptad repeat region 2
consists of shortened HR1 and HR2 domains linked together by a GGGGS linker in plac
substitution, and a C-terminal 6xHis tag. (B) SDS-PAGE of the expressed and puriﬁed pr
elution (E) fractions. (C) A crystal structure of the gp41-HR1-54Q (pdb: 3K9A) (Shi et
complex (pdb: 27R) formed by two peptides containing the FPPR-HR1 and HR2-MPEbeing used is able to preserve the correct conformation of critical
neutralizing epitopes.
As a part of our efforts to develop gp41-based HIV-1 vaccine
candidates, one of our goals has been to better understand the
relationship between antigenic structures and their immunogenic
properties. Towards this goal, we generated various gp41 con-
structs containing the MPER. One of these constructs, gp41-HR1-
54Q, contains a portion of HR1 connected to HR2 by a short linker,
followed by the MPER and a 6xHis tag. Not surprisingly, structural
analyses of this construct indicated that it forms a stable six-helix
bundle, which represents a post-fusion state (Shi et al., 2010).
However, considering that the MPER was extended away from the
six-helix bundle and that it was efﬁciently recognized by bnAbs
2F5, Z13e1 and 4E10 (Shi et al., 2010), we evaluated its immuno-
genic properties in rabbits. Although our antigen elicited strong
antibody responses against the C-terminal end of the MPER that
harbors 4E10 and 10E8 epitopes, no neutralizing activity was
detected. Despite this failure, the results of our study demonstrate
that the region targeted by 4E10 and 10E8 can be made highly
immunogenic, even in the context of a large protein.Results
Rationales for gp41-HR1-54Q design and its structure
For designing an immunogen based on gp41, we wanted to
(1) incorporate as much of gp41 as possible in order to provide suf-
ﬁcient helper T cell epitopes; (2) make sure that critical neutralizing
epitopes on the MPER are accessible (viz. 2F5, Z13e1 and 4E10; 10E8
was not discovered at the time this study began); (3) ensure that the
antigen is expressed efﬁciently, rendered soluble and easy to purify;
and (4) minimize the immunodominant epitopes that induce non-
neutralizing antibodies. One of the constructs we generated, gp41-
HR1-54Q, is shown in Fig. 1A. The immunodominant C-C loop
between the HR1 and HR2 was replaced with a GGGGS linker. Con-
comitantly, the C- and N-terminal ends of HR1 and HR2 were also
trimmed by six and two amino acids, respectively. While this ﬂexible
linker allowed the HR1 and HR2 domains to freely interact with each
other, we hypothesized that replacement of the C-C Loop with then at the top consisting of FP (fusion peptide), FPPR (fusion peptide proximal region),
) and MPER (membrane-proximal external region). In comparison, gp41-HR1-54Q
e of the C-C loop. The construct also has an N-terminal T7 expression tag, K683Q
otein stained with Coomassie blue showing total (T), supernatant (S), pellet (P) and
al., 2010) indicating individual domains. (D) A crystal structure of the post fusion
R domain (Buzon et al., 2010).
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domain. Secondly, the fusion peptide (FP) was removed to enhance
solubility. Furthermore, the fusion peptide-proximal region (FPPR)
between FP and HR1 was removed to eliminate any possible inter-
actions between FPPR and MPER, which could interfere with recog-
nition by bnAbs.
As shown in Fig. 1B, gp41-HR1-54Q was expressed at high levels
(4120mg/l of puriﬁed protein). Although the protein fractionated in
insoluble inclusion bodies, the protein could be readily solubilized with
urea, refolded by step-wise removal of urea, and puriﬁed to homo-
geneity (Shi et al., 2010). Although our original intent was to remove
the T7Tag by cleaving it with trypsin, as we previously observed that
other potential digestion sites were resistant (data not shown), the tag
also could not be cleaved, suggesting inaccessibility of the site. As
shown by the crystal structure of the protein (Fig. 1C; (Shi et al., 2010)),
HR1 and HR2 domains formed a highly stable six-helix bundle struc-
ture. The N-terminal eight amino acids of MPER were also highly
ordered (662ALDKWASL669). The N-terminal 12 residues containing the
T7Tag, as well as the last eight residues (676TNWLWYIQ683) and the
6xHis tag were not ordered and their structures could not be deﬁned.
In addition, the side chains of six residues at the end (670WNWFDI675)
could not be resolved, suggesting some ﬂexibility. In contrast to the
structure of our gp41-HR1-54Q, a crystal structure of two peptides
encompassing FPPR-HR1 (a.a. 528–581) and HR2-MPER (a.a. 628–683)
regions (Fig. 1D; (Buzon et al., 2010)), which was reported nearly at the
same time of our structural study, indicated that FPPR interacts with
MPER to enhance stability of the six-helix bundle. As a result, theMPER
region became highly ordered and its structure could be resolved fur-
ther downstream to Y681. Thus, the structural state of our immunogen
might represent a “near post-fusion”, rather than the “post-fusion”, in
regards to the MPER.
Antigenicity and immunogenicity of gp41-HR1-54Q
We have previously shown that gp41-HR1-54Q could be efﬁ-
ciently recognized by three bnAbs against MPER (2F5, Z13e1 and
4E10; (Shi et al., 2010)). 10E8, which was more recently isolated,
also binds the protein, albeit with lower afﬁnity (data not shown;Fig. 2. Antibody Titers. Sera from six immunized rabbits (R1-R6) were tested for bindin
used as a negative control.Fig. 5). This is likely due to the fact that our immunogen contains
K683Q substitution and that K or R683 is one of the amino acid
residues recognized by 10E8 (Huang et al., 2012). Since these
results indicated that the epitopes targeted by the bnAbs were
accessible and could fold into correct conformations, we pro-
ceeded to evaluate the immunogenicity of gp41-HR1-54Q.
Six rabbits were immunized with gp41-HR1-54Q. Zn-chitosan
was used as an adjuvant/delivery platform, which we have
recently shown to induce strong antibody responses against
gp120-based antigens (Qin et al., 2014a). Zn-chitosan was parti-
cularly well suited for our immunogen compared to many adju-
vants that are oil/lipid-based considering that the MPER regions is
highly hydrophobic. Rabbits were immunized four times sub-
cutaneously on weeks 0, 4, 9 and 15. Pre- and post-immune sera (2
weeks post-immunization) were collected and antibody titers
were determined by ELISA against the immunogen (Fig. 2). Strong
antibody responses were observed in all of the animals. In parti-
cular, we were quite surprised to see end-point antibody titers
approaching nearly 1107 even after only a single immunization.
Antibody titers increased substantially after the second immuni-
zation in most of the animals resulting in end-point titers between
1107 and 1108; however, titers did not increase further after
the third or the fourth immunizations, indicating that antibody
responses reached the maximum level after two immunizations.
Despite having induced high levels of antibodies against gp41-
HR1-54Q, none of the sera exhibited neutralizing activity against
HIV-1 pseudoviruses in a standard TZM-bl cell based neutraliza-
tion assay (data not shown).
Detailed characterization of antibody responses
Despite failing to exhibit neutralizing activity, understanding
the properties of antibodies elicited is important as they may
provide hints as to why they failed to neutralize, and facilitate
designing better immunogens. Towards this goal, immunogenic
epitope mapping analyses were conducted by ELISA using various
protein fragments and peptides spanning different segments of
gp41-HR1-54Q (Fig. 3).g to gp41-HR1-54Q after each of the four immunizations. Pre-immune serum was
Fig. 3. Mapping of Immunogenic Epitopes. Sera after fourth immunization were tested for binding against N36 peptide (HR1), C34 peptide (HR2), MPER peptide, gp41-HR1-
HR2 (comprised of HR1 and HR2 domains) and gp41-54Q (comprised of HR2 and MPER domains). Purple spheres indicate ELISA A450 values for individual rabbits while the
average values are plotted with red triangles. The amino acid sequences of N36, C34 and MPER, are compared with our antigen above the graph (conserved residues in black;
differences in red). ELISA was also performed against biotinylated 10-mer peptides spanning both HR2 and MPER domains. For each 10-mer, a mixture of N-terminus
biotinylated (N-B10-mer) and C-terminus biotinylated (C-B10-mer) peptides were used. The amino acid sequence of each 10-mer peptide is indicated by horizontal brackets.
The ﬁrst peptide (MEWEREISNY) and terminal peptides (DITNWLWYIK) are marked with an asterisk to indicate slight sequence differences from the original antigen. The
three most immunogenic peptides, along with two adjacent peptides, are indicated separately and the important binding residues are highlighted. The core binding epitopes
for 2F5, 4E10 and 10E8 bnAbs are also indicated.
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NIH repository, that cover the entire length of the immunogen: HR1
(N36), HR2 (C34) and MPER (661LELDKWASLWNWFDITNWLWYIK683).
Despite some sequence differences in the N-terminal half of the C34
peptide, it was used since the cluster II region was quite conserved.
Although not unexpected, antibodies against N36 were not detected.
Considering that HR1 forms the inner core of the six-helix bundle, it is
possible that they are simply not exposed enough to elicit antibody
responses. In this regard, it was surprising to see little to no reactivity
against C34 or MPER peptides since they are well exposed. This lack of
reactivity could be due to a possibility that the vast majority of the
antibodies are against non-linear epitopes and that these peptides do
not contain the full structural elements necessary to form the epitopes.
Alternatively, these peptides simply might not be able to fold into con-
formations that mimic the structure of the whole protein. Yet, another
possibility is that the way in which they are coated onto the surface of
ELISA plates hides the epitopes or sterically hinder efﬁcient antibody
binding. Some differences in the amino acid sequences in the N-terminal
half of the C34 peptide with our immunogen could also contribute.
To further characterize antibodies, two larger protein fragments
were used: gp41-HR1-HR2 and gp41-54Q, which are similar to
gp41-HR1-54Q but lack either MPER or HR1, respectively (Fig. 3).
Not surprisingly, HR1-HR2, which would form a stable six-helix
bundle, was efﬁciently recognized, indicating that a large propor-
tion of antibodies recognize non-linear, or highly conformational
epitopes on the six-helix bundle. But, what was interesting was
that gp41-54Q, which is unable to form a six-helix bundle, was
also well recognized. This suggested that gp41-54Q folded into a
structure that is different from C34 or MPER peptides individually.
Alternatively, although not exclusively, the two segments joined
together may have allowed the protein to expose epitopes when
coated onto the ELISA plate.
To identify epitopes recognized by antibodies that bind gp41-54Q,
we conducted ELISA with overlapping “10-mer” peptides (Fig. 3).
However, rather than coating plates with peptides directly using the
traditional method, peptides were biotinylated and layered onto
streptavidin-coated plates. Considering that the peptides are very
short, we suspected that direct coating of the peptides onto plates
could potentially mask epitopes. Since antibodies could bind at either
N- or C-terminal ends of the peptides, peptides were biotinylated ateither ends of the peptides, thereby generating two sets of biotiny-
lated peptides. We rationalized that using two different sets of the
peptides would enhance our ability to detect antibody binding. Fur-
thermore, two glycine residues were inserted as a spacer to avoid
steric clashes between antibodies and the plate. To minimize the
amount of work, wells were coated with both types of peptides
simultaneously. Surprisingly, high levels of antibodies were detected
against a number of peptides (Fig. 3). Although there were some
animal-to-animal variations, overall, the MPER was more immuno-
genic than HR2. The three most immunogenic peptides were
671NWFDITNWLW680, followed by 668SLWNWFDITN677 and
665KWASLWNWFD674. The common amino acid residues on these
peptides are 671NWFD674, suggesting they might play a critical role.
Consistent with this interpretation, the reactivity of adjacent peptides
that lack NWFD (662ALDKWASLWN671 and 674DITNWLWYIK683)
decreased precipitously.
Quantiﬁcation of antibodies against 671 peptide
The 671 peptide (671NWFDITNWLW680) encompasses the
entire 4E10 epitope and most of the 10E8 epitope, which extends
further out to K/R683 (Cardoso et al., 2005; Huang et al., 2012).
Since it was the most immunogenic peptide in the region that
encompasses HR2 and MPER, we were curious about the amount
of antibodies directed at this peptide. Antibody levels were com-
pared with those directed against HR1-HR2 six-helix bundle. As
shown in Fig. 4 (left panel), all six animals mounted strong anti-
body responses against the six-helix bundle with end-point titers
reaching 2105. While this is high, it was at least 100-fold less
than the titer against the whole immunogen (Fig. 2), indicating
that there are signiﬁcant levels of antibodies directed against other
epitopes. In contrast, antibody levels against the 671 peptide
varied from animal-to-animal, with end-point titers ranging from
about 1104 to greater than 2105 (Fig. 4, right panel). Con-
sidering that the 671 peptide is signiﬁcantly smaller than HR1-
HR2 six-helix bundle (7-fold), this result indicates that the
peptide is highly immunogenic in the context our gp41-HR1-54Q.
Fig. 4. Antibody titers against six helix bundle and MPER peptide. Sera after fourth
immunization showed strong binding antibody titers against gp41-HR1-HR2.
Binding antibody titers were also high against the biotinylated, 10-mer 671 peptide
that harbors the complete 4E10 epitope and the partial 10E8 eptiope suggesting
strong response against MPER.
Fig. 5. Competition assay against bnAbs. Sera after fourth immunization could
compete against both 4E10 and 10E8 for gp41-HR1-54Q binding.
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Although antibodies bound biotinylated 671 peptides, they did
not bind the full length, unbiotinylated MPER peptide. To deter-
mine whether antibodies that target the 671 peptide could indeed
bind the epitopes recognized by 4E10 or 10E8 in the context of
gp41-HR1-54Q, we conducted antibody competition analyses with
the two mAbs. As shown in Fig. 5, both 4E10 and 10E8 could be
competed away with antisera in a dose-dependent manner. 10E8
was more easily competed, which is likely due to the fact that
gp41-HR1-54Q has Q at position 683, instead of K or R, which is
one of the residues important for 10E8 binding. Although the assay
might not prove that antibodies bind exactly at the same epitope,
it does conﬁrm that antibodies do indeed bind at or near the 4E10
and 10E8 binding site close enough to compete.
The antibody titers against the 671 peptide and their ability to
compete with 4E10 or 10E8 did not seem to have clear correlation.
For example, rabbit #3, which showed the highest antibody titer,
was best able to compete with 4E10 or 10E8. However, there were
a few notable exceptions. For example, although rabbit #5 had
lower antibody titer against the 671 peptide than rabbits #1, #4
and #6, antibodies from the animal were better able to compete
with 4E10 and 10E8. Another example is rabbit #2, which showed
the lowest antibody titer against the peptide. While it competed
poorly against 4E10, it competed better than rabbit #4 and com-
peted equally with rabbits #1 and #6 against 10E8. These results
reveal complexity in evaluating antibody responses and that
multiple parameters must be considered, including quantity, afﬁ-
nity, epitope targets and antigens being used for analyses.
Fine mapping analyses of antibodies targeting near 4E10/10E8
epitopes
To further deﬁne amino acid residues critical for antibody
recognition, ELISA was conducted using a panel of 13-mer
(671NWFDITNWLWYIK683) alanine scanning mutant peptides.
First, ELISA was done with the wild type peptide (Fig. 6A). Due to
signiﬁcantly higher levels of antibodies against the peptide for
rabbits #3, #5 and #6, higher dilution of antisera was used for the
three rabbits (1:2700 compared to 1:100 for the other rabbits) to
avoid oversaturation. As a positive control, effects of mutations on
4E10 binding were evaluated. As shown in Fig. 6B, mutations at
N671, W672, D674, and T676 severely affected 4E10 binding.
Mutations at F673, I675 and L679 also affected binding to a lesser
extent. It has been shown that mutations at N671 and D674, bothof which lie on the non-neutralizing face, affect 4E10 binding
because these residues are critical for maintaining the alpha
helical conformation of C-terminal MPER peptides (Brunel et al.,
2006). Although W680 is important for neutralization, it is not
critical for binding (Brunel et al., 2006; Zwick et al., 2005). Thus,
these results are consistent with previously published report
(Brunel et al., 2006) and validate our assay.
ELISA results from the six rabbits varied signiﬁcantly from
animal-to-animal. In general, three patterns were observed:
(1) rabbits #1 and #2, (2) rabbits #3 and #4, and (3) rabbits #5 and
#6. For rabbits #1 and #2, mutations at D674 and N671 affected
binding the most, followed by mutations at F673, N677, W678 and
L679 (Fig. 6C). Mutations at I675 and T676 also affected, albeit
weakly. For rabbits #3 and #4, mutations at D674 and N671 also
affected binding (Fig. 6D). However, none of the mutations at other
sites (with the exception of F673) signiﬁcantly affected binding. It
should be noted that these assays were conducted with polyclonal
sera. Thus, one possible explanation is that a large diversity of
antibodies was induced in these animals such that a mutation at a
single site would not result in signiﬁcantly reduced binding. In
contrast, the affects of mutations on antibody binding were quite
severe for rabbits #5 and #6 (Fig. 6E); virtually all mutations,
except for W672 and I682, had affected binding. As with all other
rabbits, the mutation at D674 affected binding most severely,
possibly due to the importance of this residue for folding into a
stable alpha helix. Other critical residues were N671, F673, T676,
N677 and W678. Mutations at L679 and W680 also affected, albeit
weakly. Y681 was also critical, but only for rabbit #5. The fact that
mutations strongly affected antibody binding for rabbits #5 and
#6, in contrast to rabbits #3 and #4, suggested that a limited
number of highly dominant antibodies might have been generated
in rabbits #5 and #6.
The epitope recognized by 4E10 is 672WFDITNWLW680
(Cardoso et al., 2005). 10E8 has a slightly larger footprint,
671NWFDITNWLWYIR683 (Huang et al., 2012). The results from the
ELISA with alanine scanning mutant peptides clearly showed that
residues important for recognition by the rabbit sera overlap with
those critical for 4E10 and 10E8 binding (bold/underlined). Despite
this, we did not detect any neutralizing activity in our rabbit sera.
To better understand possible reason(s) for the lack of neutralizing
activity, the amino acid residues critical for binding were plotted
onto a peptide that was co-crystallized with 10E8 (Fig. 7). The
analyses were done based on an assumption that the C-terminal
13-mer peptide used for the ELISA, and the corresponding residues
on gp41-HR1-54Q, also existed in an alpha helix. The analyses
revealed that the critical residues for 4E10/10E8 and rabbit anti-
bodies were on different faces of the alpha helix. For rabbits #5
Fig. 6. PepScan analysis of the C-terminus end of MPER. (A) Sera after fourth immunization were tested for binding to a biotinylated wild type 13-mer peptide
(671NWFDITNWLWYIK683). The sera dilutions were normalized to give comparable binding signal (R1, R2 and R4 were tested at 100-fold dilution while R3, R5, and R6 were
tested at 2700-fold dilution). (B) Binding of 4E10 (1 ug/ml) to mutant peptides was evaluated as a positive control. (C–E) The same dilutions of rabbit serum samples were
tested for binding mutant peptides. Results are shown as the percentage of binding to the wild type peptide shown in panel (A). Three different patterns of antibody
responses are shown on different columns with the average calculated at the bottom. The labeling of the mutant peptides are color coded based on the extent of reduction in
binding as follows: red: o31%; orange: 31–61%; green 61–80%.
Fig. 7. Structural comparison of critical residues targeted by antibodies induced in rabbits with those of 10E8 and 4E10. (A) A co-crystal structure of a peptide bound to 10E8
is shown (pdb: 4G6F). Amino acid residues critical for binding by 10E8 (W672 and R683) and antibodies from rabbits #5 and #6 (N677 and W678) are shown in green and
red, respectively. The residues important for binding by both antibodies (F673 and T676) are shown in blue. Only the most critical residues are shown. N671 and D674 are not
shown, as their affect on binding may be indirect. L679, which moderately affects binding of 4E10, as well as rabbits #1, #2, #5, and #6, is shown in magenta. Y681 (cyan),
which affected rabbit #5 quite signiﬁcantly is also shown. Heavy (H) and Light (L) chains are indicated. (B, C) Views of the peptide bound to 10E8 from different angles. Panel
C shows a view through the axis of the alpha helix at the C-terminus (from N671 to R683), which reveals that residues recognized by 4E10/10E8 and rabbit antibodies are
situated on different faces of the helix. (D) A crystal structure of a peptide bound to 10E8 illustrating the locations of N671 and D674, which shows that these two residues lie
on the binding face of the helix for rabbit antibodies. Thus, they could be directly involved in binding antibodies in addition to being important for maintaining alpha helix
conformation of the peptide.
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and T676 (Fig. 7C). For rabbits #1 and #2, they were completely on
the opposite side, with overlap at I675 and L679 on one side and
F673 on the other. Thus, the likely reason why rabbit antibodies
failed to neutralize HIV-1 is because the faces of the alpha helix
recognized by them might not be fully accessible on the trimeric
envelope structure on the virion surface.Discussion
Despite many failures to induce potent bnAbs against gp41
MPER during the past decades, it remains an important goal
towards developing a protective AIDS vaccine. Towards this goal,
we have been designing various MPER-based immunogens, one of
them being gp41-HR1-54Q. We had previously reported its crystal
structure (Shi et al., 2010) and its immunogenicity was examined
in this study. Although we failed to induce bnAbs using this con-
struct, we believed it was important to characterize its immuno-
genic properties in detail to learn why it may have failed. Indeed,
we have made a number of important observations, which we
believe would facilitate future vaccine development efforts.
First, strong immune responses were induced against gp41-
HR1-54Q in rabbits. The antibody titers elicited seemed to be
much stronger than previously characterized gp41-based immu-
nogens, reaching nearly 1107 end-point titers even after a single
immunization. This could be attributed to a potent adjuvant effect
of Zn-chitosan (Qin et al., 2014a; Seferian and Martinez, 2000). It
could also be attributed to a stable structure of the six-helix
bundle formed by HR1 and HR2. Strong antibody responses
against the six-helix bundle, especially against the cluster II region
within HR2, have also been observed in HIV-1 infected patients
(Alam et al., 2008; Frey et al., 2010). It should be noted, however,
that the end-point antibody titers against HR1/HR2 six-helix
bundle were only 2105 (Fig. 4), about 100-fold less than the
titers against the whole antigen. This suggests that other regions/
conformations of the antigen were also immunogenic. Indeed,
signiﬁcant levels of antibodies were also detected against gp41-
54Q (Fig. 3), a construct that contains just HR2 and MPER and
would not be able to form the six-helix bundle. Substantial anti-
body levels were also detected against MPER using biotinylated
10-mer peptides, although not when the 23 amino acid MPER
peptide was used. In this regard, it should be pointed out that
antibody detection by ELISA depends signiﬁcantly on what protein
or peptide fragments are used and how they are attached to plates
(i.e. direct coating vs. using biotinylated peptides).
Although we were able to induce high titers of antibodies
against MPER using gp41-HR1-54Q, they failed to exhibit neu-
tralizing activity. Detailed mapping analyses indicated that the
antibodies targeted epitopes that overlap with those of 4E10 and
10E8. However, the critical residues of the epitopes seemed to lie
on the face of the MPER alpha helix perpendicular to, or opposite
side of, the residues recognized by 4E10 and 10E8 (Figs. 6 and 7).
The crystal structure revealed that the MPER region of our gp41-
HR1-54Q is highly ﬂexible and disordered; the very C-terminal
eight residues of MPER as well as the 6xHis tag could not be
observed and the last eight residues that could be seen could be
resolved only at the level of the backbone atoms (Shi et al., 2010).
Being in a “near post-fusion” state without FPPR, it appears that
MPER on our immunogen is ﬂexible enough to be recognized by
4E10 and 10E8 as well as the antibodies induced in rabbits.
However, on the native trimeric envelope structure on virus par-
ticles, ﬂexibility of MPER is likely more limited being not only
bound to the membrane, but also connected to a large cytoplasmic
domain. In such a rigid state, it is possible that the epitopes being
recognized by the rabbit antibodies are not fully exposed on eitherthe pre-fusion structure or on fusion intermediates that may exist
during the fusion process. Alternatively, these epitopes might be
exposed, but the angle of approach required for binding might not
be possible in the context of the protein situated on the viral
membrane.
Given that 4E10 and 10E8 epitopes are accessible on our
immunogen, we are unsure as to why antibody responses were not
induced against these epitopes. One possibility is that the epitopes
that induced antibodies is inherently and overwhelmingly more
immunogenic such that faster antibody responses against these
epitopes prevented any immune responses being mounted against
the 4E10 or 10E8 epitopes (due to steric competition). If this was
the case, perhaps reducing immunogenicity of the epitopes by
amino acid substitutions or by masking (e.g. by glycosylation,
PEGylation or immune complexing) could render 4E10/10E8 epi-
topes more immunogenic. Another possibility is that the epitopes
on our HR1-54Q that induced antibodies are more favorably tar-
geted than 4E10/10E8 epitopes when presented in the context of a
stable six-helix bundle. In this case, immunogens with less com-
pletely formed (or less stable) six-helix bundle structures that
might mimic fusion intermediates could be better immunogens.
Alternatively, although not exclusively, immunogens that include
the transmembrane domain (with or without the cytoplasmic tail)
might be necessary to provide proper rigidity of, or spacing
between, the three MPER on a trimeric structure that would hide
the non-neutralizing face of the 4E10/10E8 peptide.
Recently, there have been a couple of reports describing
immunogenic properties of antigen constructs very similar to ours,
which also contained HR1, HR2 and MPER domains. In a report by
Vassell et al. (Vassell et al., 2015), authors evaluated immunogeni-
city of several constructs comprised of MPER with different lengths
of HR1 and HR2 in rabbits. Constructs were made with or without
two different trimerization domains (GCN4 or foldon). The immu-
nogens were based on HIV-1HXB2 strain, in contrast to ours, which
was based on M group consensus sequence (MCON6). Compared to
our study, antibody responses were signiﬁcantly weaker with end-
pointers reaching only 4–8104. More importantly, antibody titers
directed against MPER ranged only between about 100 and 5,000,
which are 100- to 1000-fold less than what we observed. Two
notable differences between the two studies are (1) we used 200 mg
of antigen per immunization while they used 50 mg, and (2) we
used Zn-chitosan as an adjuvant in contrast to their study, which
used complete/incomplete Freund's adjuvant. Thus, our study
demonstrates that it is possible to overcome poor immunogenicity
of MPER by using a suitable antigenwith appropriate dosage and an
adjuvant. In this regard, one interesting observation from their
study is that of all the immunogens they evaluated, the construct
that induced best antibody responses against MPER was FDA26,
which lacked a C-terminal trimerization domain, suggesting that
rigidity of the region makes it less immunogenic.
In contrast, Wang et al. (Wang et al., 2011) reported the elicita-
tion of neutralizing antibodies, albeit with limited breadth and
potency, in rabbits upon immunization with a similar gp41 antigen
named NCM(TAIV). This construct, based on HXB2 strain, contains
N36 HR1 connected to C34 HR2 via a GGGKLGGG liner followed by
MPER. It also carries two point mutations: T569A and I675V, which
have been reported to increase the exposure of the neutralizing
epitopes in the MPER region (Blish et al., 2008). Interestingly, the
same construct without the mutations or with a single mutation
individually, induced much weaker antibody responses, especially
against MPER region. The exact mechanism of enhanced immune
responses rendered by these mutations, or the nature of neu-
tralizing activity, currently remains unknown. Furthermore, the
absence of detailed epitope mapping data in the report and the lack
of further follow up studies limit our ability to fully compare
immunogenic properties of NCM(TAIV) and gp41-HR1-54Q.
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covering potent bnAbs against HIV-1 (Bonsignori et al., 2011;
Gaebler et al., 2013; Gray et al., 2011; Scheid et al., 2009; Walker et
al., 2009; Wardemann et al., 2003) and determining high-
resolution structures of the bnAbs (Huang et al., 2012; Julien et
al., 2013b; Pejchal et al., 2011; Scharf et al., 2014; Zhou et al., 2010)
as well as novel envelope antigens (e.g. germline targeting eOD-
GT6 and stable trimeric SOSIP gp140; (Bartesaghi et al., 2013;
Jardine et al., 2013; Julien et al., 2013a; Lyumkis et al., 2013)).
While structure-based, rational immunogen design can facilitate
vaccine development efforts, much of vaccine research still
remains an empirical process because immunology still is a “black
box” and we are unable to predict immunological responses to a
given immunogen with any precision. As such, vaccine develop-
ment efforts remain a reiterative process for which understanding
why a vaccine candidate failed to induce desired immune response
is important. Our study reveals detailed information on immu-
nogenic properties of gp41-HR1-54Q. The availability of its crystal
structure allows us to have better understanding of the relation-
ship between antigenic structures and their immunogenic prop-
erties. We hope to use this information to design next generation
of MPER-based immunogens.Conclusion
A novel, M group consensus sequence-based HIV-1 gp41 MPER
immunogen (gp41-HR1-54Q) was generated and its immuno-
genicity was evaluated in rabbits. Our vaccine regimen using Zn-
chitosan as an adjuvant induced potent antibody responses against
the immunogen, especially against the C-terminal 13 amino acid
peptide that contains epitopes recognized by bnAbs 4E10 ad 10E8.
Neutralizing activity was not detected. However, detailed epitope
mapping analyses revealed amino acid residues recognized by
induced antibodies. These results provide critical information for
designing the next generation of MPER-based immunogens.Materials and methods
Rabbit immunization
Female New Zealand white rabbits (2.5–3 kg) were purchased
from Charles River or Myrtle's Rabbitry and housed under speciﬁc
pathogen free environments. Rabbits were cared for and used
following animal protocols approved by IACUC at Case Western
Reserve University or Iowa State University. To evaluate immu-
nogenic properties of gp41-HR1-54Q, which was expressed and
puriﬁed as previously described (Shi et al., 2010), rabbits were
immunized subcutaneously with the protein four times (weeks 0,
4, 9 and 15) using Zn-chitosan as an adjuvant. Zn-chitosan was
prepared and used as previously reported (Qin et al., 2014a). The
protein was loaded onto Zn-chitosan at a ratio of 200 mg to
200 mg, respectively, in phosphate-buffered saline (PBS, pH 8.0) by
continuous agitation for three hours at room temperature. Rabbits
were immunized with 200 mg of gp41-HR1-54Q per each
immunization.
Enzyme-linked immunosorbent assay (ELISA)
To determine the end point titers, gp41-HR1-54Q was coated
onto 96-well Nunc-Immuno Plates (Nunc; # 439454) at 30 ng/well
using antigen coating buffer (15 mM Na2CO3, 35 mM NaHCO3,
3 mM NaN3, pH 9.6) overnight at 4 °C. Uncoated surface was
blocked using 200 μl of PBS (pH 7.5) containing 2.5% skim milk
and 25% Fetal Bovine Serum (FBS) for 1 h at 37 °C. The plates weresubsequently washed 10 with 0.1% Tween 20 in PBS. Rabbit sera
were serially diluted (three folds) in the blocking buffer, and
100 μl was added to each well and incubated for 2 h at 37 °C. The
plates were washed 10 , and horseradish peroxidase (HRP)-
conjugated secondary antibody (goat anti-rabbit, 1:3000 dilution;
Thermo Scientiﬁc; Cat #31430) was added to each well and
incubated (100 ml, for 1 h at 37 °C). Wells were washed 10 and
developed by adding 100 ml TMB HRP-substrate (Bio-Rad) for
10 min. Reactions were stopped with 50 ml of 2 N H2SO4. Plates
were read on a microplate reader (Versamax by Molecular Devi-
ces) at 450 nm. All experiments were performed in duplicates.
For ELISA with other proteins (gp41-HR1-HR2, gp41-54Q) and pep-
tides (N36, C34), coating antigen amounts used were molar equivalents
to that used for gp41-HR1-54Q (30 ng/well). The details of the expres-
sion and puriﬁcation of gp41-HR1-HR2 and gp41-54Q will be described
elsewhere. As described in the results section and Fig. 3, constructs for
these proteins were the same as gp41-HR1-54Q, except for the lack of
MPER or HR1 domain respectively. The gp41-HR1-HR2 protein ended at
L661 with RSELVPR thrombin cleavage site at the C-terminus. For ELISA
with overlapping peptides, 10-mer peptides were biotinylated with EZ-
Link Sulfo-NHS-LC Biotin as per the manufacturer’s instructions (Thermo
Scientiﬁc, Cat #21327). A mixture of both N- and C-terminally biotiny-
lated peptides (100 ng each) were used for coating onto streptavidin-
coated plates (Thermo Scientiﬁc, Cat #15500). For alanine scan analysis,
13-mer 671NWFDITNWLWYIK683 peptides were also biotinylated at the
C-terminal K683. All other steps for ELISA were the same as
described above.
Competition assays
For competition assays, plates were coated overnight with 30 ng/
well of gp41-HR1-54Q. Antibodies used for competition included
4E10 (Stiegler et al., 2001) and 10E8 (Huang et al., 2012) at a ﬁnal
concentration of 1 μg/ml. The rest of the assay was performed as
previously described (Qin et al., 2014b).
Neutralization assays
TZM-bl cell-based HIV-1 pseudovirus neutralization assays
were done as previously described (Li et al., 2005; Qin et al.,
2014a; Wei et al., 2002). Viruses tested were SF162 (tier 1A, clade
B), MW965.26 (tier 1A, clade C), and MN.3 (tier 1A, clade B).
Murine leukemia virus Env-pseudotyped virus was used as a
negative control.Acknowledgments
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